MwanzoANTH • OTCMKTS
add
Anthera Pharmaceuticals Inc
Bei iliyotangulia
$ 0.00
Thamani ya kampuni katika soko
30.00 USD
Wastani wa hisa zilizouzwa
elfu 3.81
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
OTCMKTS
Habari za soko
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | 2017info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | — | — |
Matumizi ya uendeshaji wa biashara | 7.94M | -28.30% |
Mapato halisi | -26.87M | 51.60% |
Kiwango cha faida halisi | — | — |
Mapato kwa kila hisa | -3.80 | 70.53% |
EBITDA | -36.15M | 36.48% |
Asilimia ya kodi ya mapato | — | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | 2017info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 2.20M | -89.46% |
Jumla ya mali | 3.67M | -84.35% |
Jumla ya dhima | 9.17M | -13.70% |
Jumla ya hisa | -5.50M | — |
hisa zilizosalia | 23.40M | — |
Uwiano wa bei na thamani | -0.00 | — |
Faida inayotokana na mali | -167.77% | — |
Faida inayotokana mtaji | -619.42% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | 2017info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -26.87M | 51.60% |
Pesa kutokana na shughuli | -36.90M | 24.57% |
Pesa kutokana na uwekezaji | — | — |
Pesa kutokana na ufadhili | 18.25M | -22.58% |
Mabadiliko halisi ya pesa taslimu | -18.65M | 28.58% |
Mtiririko huru wa pesa | -23.15M | 18.17% |
Kuhusu
Anthera Pharmaceuticals, Inc. is an American biopharmaceutical company focused on developing and commercializing products to treat serious conditions associated with cystic fibrosis, inflammation and autoimmune diseases. Liprotamase, Anthera's leading drug candidate which is being developed for exocrine pancreatic insufficiency is currently in Phase 3 clinical trials, and A-623 for the treatment of IgA nephropathy is currently in Phase 2 clinical trial. Wikipedia
Ilianzishwa
2004
Makao Makuu
Tovuti
Wafanyakazi
21
